BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Vanhove T, Vermeulen T, Annaert P, Lerut E, Kuypers DRJ. High Intrapatient Variability of Tacrolimus Concentrations Predicts Accelerated Progression of Chronic Histologic Lesions in Renal Recipients. Am J Transplant. 2016;16:2954-2963. [PMID: 27013142 DOI: 10.1111/ajt.13803] [Cited by in Crossref: 70] [Cited by in F6Publishing: 63] [Article Influence: 11.7] [Reference Citation Analysis]
Number Citing Articles
1 Schwartz JJ, Wilson S, Shi F, Elsouda D, Undre N, Kumar MSA. Prolonged-Release vs Immediate-Release Tacrolimus Capsules in Black vs White Kidney Transplant Patients: A Post Hoc Analysis of Phase III Data. Transplant Proc 2018;50:3283-95. [PMID: 30577198 DOI: 10.1016/j.transproceed.2018.08.050] [Reference Citation Analysis]
2 Ko H, Kim HK, Chung C, Han A, Min SK, Ha J, Min S. Association between medication adherence and intrapatient variability in tacrolimus concentration among stable kidney transplant recipients. Sci Rep 2021;11:5397. [PMID: 33686160 DOI: 10.1038/s41598-021-84868-5] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
3 van Gelder T. A new method to calculate intra-patient variability in tacrolimus concentrations. Br J Clin Pharmacol 2021. [PMID: 33948976 DOI: 10.1111/bcp.14865] [Reference Citation Analysis]
4 Vanhove T, Goldschmeding R, Kuypers D. Kidney Fibrosis: Origins and Interventions. Transplantation 2017;101:713-26. [PMID: 27941433 DOI: 10.1097/TP.0000000000001608] [Cited by in Crossref: 44] [Cited by in F6Publishing: 23] [Article Influence: 8.8] [Reference Citation Analysis]
5 Bunthof KLW, Al-Hassany L, Nakshbandi G, Hesselink DA, van Schaik RHN, Ten Dam MAGJ, Baas MC, Hilbrands LB, van Gelder T. A randomized crossover study comparing different tacrolimus formulations to reduce intrapatient variability in tacrolimus exposure in kidney transplant recipients. Clin Transl Sci 2021. [PMID: 34905302 DOI: 10.1111/cts.13206] [Reference Citation Analysis]
6 Seibert SR, Schladt DP, Wu B, Guan W, Dorr C, Remmel RP, Matas AJ, Mannon RB, Israni AK, Oetting WS, Jacobson PA. Tacrolimus trough and dose intra-patient variability and CYP3A5 genotype: Effects on acute rejection and graft failure in European American and African American kidney transplant recipients. Clin Transplant 2018;32:e13424. [PMID: 30318646 DOI: 10.1111/ctr.13424] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.8] [Reference Citation Analysis]
7 Song T, Yin S, Jiang Y, Huang Z, Liu J, Wang Z, Li L, Zeng J, Fan Y, Wang X, Li X, Lin T. Increasing Time in Therapeutic Range of Tacrolimus in the First Year Predicts Better Outcomes in Living-Donor Kidney Transplantation. Front Immunol 2019;10:2912. [PMID: 31921171 DOI: 10.3389/fimmu.2019.02912] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
8 Chamoun B, Torres IB, Gabaldón A, Sellarés J, Perelló M, Castellá E, Guri X, Salcedo M, Toapanta NG, Cidraque I, Moreso F, Seron D. Progression of Interstitial Fibrosis and Tubular Atrophy in Low Immunological Risk Renal Transplants Monitored by Sequential Surveillance Biopsies: The Influence of TAC Exposure and Metabolism. J Clin Med 2021;10:E141. [PMID: 33406589 DOI: 10.3390/jcm10010141] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Gantar K, Škerget K, Mochkin I, Bajc A. Meeting Regulatory Requirements for Drugs with a Narrow Therapeutic Index: Bioequivalence Studies of Generic Once-Daily Tacrolimus. Drug Healthc Patient Saf 2020;12:151-60. [PMID: 32982466 DOI: 10.2147/DHPS.S256455] [Reference Citation Analysis]
10 Torabi J, Campbell A, Ajaimy M, Rocca JP, Graham JA. Utilization of LCP-Tacrolimus (Envarsus XR) in Simultaneous Pancreas and Kidney Transplant Recipients. Ochsner J 2018;18:190-2. [PMID: 30275776 DOI: 10.31486/toj.18.0011] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
11 Li A, Xu C, Liang P, Hu Y, Shen Y, Hu D, Li Z, Kamel IR. Role of Chemical Exchange Saturation Transfer and Magnetization Transfer MRI in Detecting Metabolic and Structural Changes of Renal Fibrosis in an Animal Model at 3T. Korean J Radiol 2020;21:588-97. [PMID: 32323504 DOI: 10.3348/kjr.2019.0646] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
12 Jouve T, Noble J, Rostaing L, Malvezzi P. An update on the safety of tacrolimus in kidney transplant recipients, with a focus on tacrolimus minimization. Expert Opinion on Drug Safety 2019;18:285-94. [DOI: 10.1080/14740338.2019.1599858] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
13 Schumacher L, Leino AD, Park JM. Tacrolimus intrapatient variability in solid organ transplantation: A multiorgan perspective. Pharmacotherapy 2021;41:103-18. [PMID: 33131078 DOI: 10.1002/phar.2480] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
14 Beck DK, Tielen M, Rechards M, Timman R, Boonstra C, Versteegh J, van de Wetering J, Zietse R, van Gelder T, Weimar W, van Saase J, van Busschbach J, Massey EK. Comparison of a home-based (multi) systemic intervention to promoting Medication AdheRence and Self-management among kidney transplant recipients with care-as-usual: the MARS randomized controlled trial protocol. BMC Nephrol 2020;21:374. [PMID: 32859157 DOI: 10.1186/s12882-020-02008-z] [Reference Citation Analysis]
15 Chavant A, Fonrose X, Gautier-Veyret E, Hilleret MN, Roustit M, Stanke-Labesque F. Variability of Tacrolimus Trough Concentration in Liver Transplant Patients: Which Role of Inflammation? Pharmaceutics 2021;13:1960. [PMID: 34834375 DOI: 10.3390/pharmaceutics13111960] [Reference Citation Analysis]
16 Fernandez HE, Amaral S, Shaw PA, Doyle AM, Bloom RD, Palmer JA, Baluarte HJ, Furth SL. The effect of transfer to adult transplant care on kidney function and immunosuppressant drug level variability in pediatric kidney transplant recipients. Pediatr Transplant 2019;23. [DOI: 10.1111/petr.13527] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
17 Cheung CY, Chan KM, Wong YT, Chak WL, Bekers O, van Hooff JP. Impact of CYP3A5 Genetic Polymorphism on Intrapatient Variability of Tacrolimus Exposure in Chinese Kidney Transplant Recipients. Transplantation Proceedings 2019;51:1754-7. [DOI: 10.1016/j.transproceed.2019.04.019] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
18 Gonzales HM, McGillicuddy JW, Rohan V, Chandler JL, Nadig SN, Dubay DA, Taber DJ. A comprehensive review of the impact of tacrolimus intrapatient variability on clinical outcomes in kidney transplantation. Am J Transplant 2020;20:1969-83. [PMID: 32406604 DOI: 10.1111/ajt.16002] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
19 Rayar M, Tron C, Jézéquel C, Beaurepaire JM, Petitcollin A, Houssel-debry P, Camus C, Verdier MC, Dehlawi A, Lakéhal M, Desfourneaux V, Meunier B, Sulpice L, Bellissant E, Boudjema K, Lemaitre F. High Intrapatient Variability of Tacrolimus Exposure in the Early Period After Liver Transplantation Is Associated With Poorer Outcomes. Transplantation 2018;102:e108-14. [DOI: 10.1097/tp.0000000000002052] [Cited by in Crossref: 16] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
20 Park Y, Lee H, Eum SH, Kim HD, Ko EJ, Yang CW, Chung BH. Intrapatient Variability in Tacrolimus Trough Levels Over 2 Years Affects Long-Term Allograft Outcomes of Kidney Transplantation. Front Immunol 2021;12:746013. [PMID: 34659243 DOI: 10.3389/fimmu.2021.746013] [Reference Citation Analysis]
21 Dew MA, Posluszny DM, DiMartini AF, Myaskovsky L, Steel JL, DeVito Dabbs AJ. Posttransplant Medical Adherence: What Have We Learned and Can We Do Better? Curr Transplant Rep 2018;5:174-88. [PMID: 30416933 DOI: 10.1007/s40472-018-0195-8] [Cited by in Crossref: 21] [Cited by in F6Publishing: 12] [Article Influence: 5.3] [Reference Citation Analysis]
22 Maier M, Takano T, Sapir-Pichhadze R. Changing Paradigms in the Management of Rejection in Kidney Transplantation: Evolving From Protocol-Based Care to the Era of P4 Medicine. Can J Kidney Health Dis 2017;4:2054358116688227. [PMID: 28270929 DOI: 10.1177/2054358116688227] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.6] [Reference Citation Analysis]
23 Lemaitre F, Tron C, Jezequel C, Verdier MC, Rayar M. Intrapatient variability in solid organ transplantation: Should we make the first move earlier? Am J Transplant 2019;19:610. [PMID: 30188607 DOI: 10.1111/ajt.15107] [Reference Citation Analysis]
24 Parodi E, La Porta E, Russo R, Marsano L, Bellino D, Paoletti E, Massarino F, Sofia A, Garibotto G, Esposito P, Murugavel A, Cappadona F, Fontana I, Viazzi F, Picciotto D. Ten-Year Efficacy and Safety of Once-Daily Tacrolimus in Kidney Transplant: A Prospective Cohort Study. Transplantation Proceedings 2020;52:3112-7. [DOI: 10.1016/j.transproceed.2020.02.149] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
25 Kuypers DRJ. Intrapatient Variability of Tacrolimus Exposure in Solid Organ Transplantation: A Novel Marker for Clinical Outcome. Clin Pharmacol Ther 2020;107:347-58. [PMID: 31449663 DOI: 10.1002/cpt.1618] [Cited by in Crossref: 31] [Cited by in F6Publishing: 24] [Article Influence: 10.3] [Reference Citation Analysis]
26 Chancharoenthana W, Leelahavanichkul A, Wattanatorn S, Avihingsanon Y, Praditpornsilpa K, Eiam-Ong S, Townamchai N. Alteration of urinary neutrophil gelatinase-associated lipocalin as a predictor of tacrolimus-induced chronic renal allograft fibrosis in tacrolimus dose adjustments following kidney transplantation. PLoS One 2018;13:e0209708. [PMID: 30576367 DOI: 10.1371/journal.pone.0209708] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
27 Brunet M, van Gelder T, Åsberg A, Haufroid V, Hesselink DA, Langman L, Lemaitre F, Marquet P, Seger C, Shipkova M, Vinks A, Wallemacq P, Wieland E, Woillard JB, Barten MJ, Budde K, Colom H, Dieterlen M, Elens L, Johnson-davis KL, Kunicki PK, Macphee I, Masuda S, Mathew BS, Millán O, Mizuno T, Moes DAR, Monchaud C, Noceti O, Pawinski T, Picard N, van Schaik R, Sommerer C, Vethe NT, de Winter B, Christians U, Bergan S. Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy: Second Consensus Report. Therapeutic Drug Monitoring 2019;41:261-307. [DOI: 10.1097/ftd.0000000000000640] [Cited by in Crossref: 131] [Cited by in F6Publishing: 46] [Article Influence: 43.7] [Reference Citation Analysis]
28 Oetting WS, Dorr C, Remmel RP, Matas AJ, Israni AK, Jacobson PA. Concepts of Genomics in Kidney Transplantation. Curr Transplant Rep 2017;4:116-23. [PMID: 29123971 DOI: 10.1007/s40472-017-0153-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
29 Del Bello A, Congy-Jolivet N, Danjoux M, Muscari F, Lavayssière L, Esposito L, Hebral AL, Bellière J, Kamar N. High tacrolimus intra-patient variability is associated with graft rejection, and de novo donor-specific antibodies occurrence after liver transplantation. World J Gastroenterol 2018; 24(16): 1795-1802 [PMID: 29713132 DOI: 10.3748/wjg.v24.i16.1795] [Cited by in CrossRef: 37] [Cited by in F6Publishing: 27] [Article Influence: 9.3] [Reference Citation Analysis]
30 Levine D, Torabi J, Choinski K, Rocca JP, Graham JA. Transplant surgery enters a new era: Increasing immunosuppressive medication adherence through mobile apps and smart watches. Am J Surg 2019;218:18-20. [PMID: 30799019 DOI: 10.1016/j.amjsurg.2019.02.018] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
31 McGillicuddy J, Chandler J, Sox L, Mueller M, Nemeth L, Baliga P, Treiber F. "Smartphone Medication Adherence Saves Kidneys" for Kidney Transplantation Recipients: Protocol for a Randomized Controlled Trial. JMIR Res Protoc 2019;8:e13351. [PMID: 31228175 DOI: 10.2196/13351] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
32 Tinti F, Umbro I, Poli L, Cappoli A, Garofalo M, Bachetoni A, D'alessandro M, Lai S, Berloco P, Mitterhofer A. Long-term Glomerular Filtration Rate and Kidney Disease: Improving Global Outcomes Stage Stability After Conversion to Once-Daily Tacrolimus in Kidney Transplant Recipients. Transplantation Proceedings 2019;51:147-52. [DOI: 10.1016/j.transproceed.2018.04.076] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
33 Dorr CR, Oetting WS, Jacobson PA, Israni AK. Genetics of acute rejection after kidney transplantation. Transpl Int 2018;31:263-77. [PMID: 29030886 DOI: 10.1111/tri.13084] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.6] [Reference Citation Analysis]
34 Kim J, Wilson S, Undre NA, Shi F, Kristy RM, Schwartz JJ. A Novel, Dose-Adjusted Tacrolimus Trough-Concentration Model for Predicting and Estimating Variance After Kidney Transplantation. Drugs R D 2019;19:201-12. [PMID: 31073875 DOI: 10.1007/s40268-019-0271-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
35 Millán O, Rovira J, Guirado L, Espinosa C, Budde K, Sommerer C, Piñeiro GJ, Diekmann F, Brunet M. Advantages of plasmatic CXCL-10 as a prognostic and diagnostic biomarker for the risk of rejection and subclinical rejection in kidney transplantation. Clin Immunol 2021;229:108792. [PMID: 34217849 DOI: 10.1016/j.clim.2021.108792] [Reference Citation Analysis]
36 Prytuła A, van Gelder T. Clinical aspects of tacrolimus use in paediatric renal transplant recipients. Pediatr Nephrol 2019;34:31-43. [DOI: 10.1007/s00467-018-3892-8] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
37 Dheer D, Jyoti, Gupta PN, Shankar R. Tacrolimus: An updated review on delivering strategies for multifarious diseases. European Journal of Pharmaceutical Sciences 2018;114:217-27. [DOI: 10.1016/j.ejps.2017.12.017] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 5.5] [Reference Citation Analysis]
38 Crespo M, Zárraga S, Alonso Á, Beneyto I, Díaz Corte C, Fernandez Rodriguez AM, Franco A, Hernández D, González-roncero FM, Jiménez Martín C, Jimeno L, Lauzurica Valdemoros L, Llorente S, Mazuecos A, Osuna A, Ramos JP, Rodríguez Benot A, Ruiz San Millán JC, Sánchez Fructuoso A, Torregrosa J, Guirado L. Monitoring of Donor-specific Anti-HLA Antibodies and Management of Immunosuppression in Kidney Transplant Recipients: An Evidence-based Expert Paper. Transplantation 2020;104:S1-S12. [DOI: 10.1097/tp.0000000000003270] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
39 Arns W, Huppertz A, Rath T, Ziefle S, Rump LC, Hansen A, Budde K, Lehner LJ, Shipkova M, Baeumer D, Kroeger I, Sieder C, Klein T, Schenker P. Pharmacokinetics and Clinical Outcomes of Generic Tacrolimus (Hexal) Versus Branded Tacrolimus in De Novo Kidney Transplant Patients: A Multicenter, Randomized Trial. Transplantation 2017;101:2780-8. [DOI: 10.1097/tp.0000000000001843] [Cited by in Crossref: 6] [Article Influence: 1.2] [Reference Citation Analysis]
40 Davis S, Gralla J, Klem P, Tong S, Wedermyer G, Freed B, Wiseman A, Cooper JE. Lower tacrolimus exposure and time in therapeutic range increase the risk of de novo donor-specific antibodies in the first year of kidney transplantation. Am J Transplant 2018;18:907-15. [PMID: 28925597 DOI: 10.1111/ajt.14504] [Cited by in Crossref: 57] [Cited by in F6Publishing: 51] [Article Influence: 11.4] [Reference Citation Analysis]
41 Alghanem SS, Soliman MM, Alibrahim AA, Gheith O, Kenawy AS, Awad A. Monitoring Tacrolimus Trough Concentrations During the First Year After Kidney Transplantation: A National Retrospective Cohort Study. Front Pharmacol 2020;11:566638. [PMID: 33658922 DOI: 10.3389/fphar.2020.566638] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
42 Nevins TE, Nickerson PW, Dew MA. Understanding Medication Nonadherence after Kidney Transplant. J Am Soc Nephrol 2017;28:2290-301. [PMID: 28630231 DOI: 10.1681/ASN.2017020216] [Cited by in Crossref: 62] [Cited by in F6Publishing: 19] [Article Influence: 12.4] [Reference Citation Analysis]
43 Larpparisuth N, Pongnatcha T, Panprom P, Promraj R, Premasathian N, Vongwiwatana A. High Intrapatient Variability in Tacrolimus Exposure Calculated Over a Long Period Is Associated With De Novo Donor-Specific Antibody Development and/or Late Rejection in Thai Kidney Transplant Patients Receiving Concomitant CYP3A4/5 Inhibitors. Ther Drug Monit 2021;43:624-9. [PMID: 33278239 DOI: 10.1097/FTD.0000000000000850] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
44 Yin S, Wang X, Huang Z, Fan Y, Song T, Lin T. Tacrolimus variability score outperforms coefficient of variation in predicting clinical outcomes of living kidney transplantation. Br J Clin Pharmacol 2021. [PMID: 33899267 DOI: 10.1111/bcp.14876] [Reference Citation Analysis]
45 Degraeve AL, Moudio S, Haufroid V, Chaib Eddour D, Mourad M, Bindels LB, Elens L. Predictors of tacrolimus pharmacokinetic variability: current evidences and future perspectives. Expert Opin Drug Metab Toxicol 2020;16:769-82. [PMID: 32721175 DOI: 10.1080/17425255.2020.1803277] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
46 Ball S. Bioequivalence of twice-daily oral tacrolimus in transplant recipients: More evidence for consensus? PLoS Med 2017;14:e1002429. [PMID: 29135980 DOI: 10.1371/journal.pmed.1002429] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
47 Xiong XF, Chen DD, Zhu HJ, Ge WH. Prognostic value of endogenous and exogenous metabolites in liver transplantation. Biomark Med 2020;14:1165-81. [PMID: 32969246 DOI: 10.2217/bmm-2020-0073] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
48 Lang S, Sharma A, Foster B, Gibson IW, Ho J, Nickerson P, Wishart D, Blydt-Hansen T. Age and sex determine conversion from immediate-release to extended-release tacrolimus in a multi-center cohort of Canadian pediatric renal transplant recipients. Pediatr Transplant 2021;25:e13959. [PMID: 33368914 DOI: 10.1111/petr.13959] [Reference Citation Analysis]
49 Taber DJ, Su Z, Fleming JN, McGillicuddy JW, Posadas-Salas MA, Treiber FA, Dubay D, Srinivas TR, Mauldin PD, Moran WP. Tacrolimus Trough Concentration Variability and Disparities in African American Kidney Transplantation. Transplantation. 2017;101:2931-2938. [PMID: 28658199 DOI: 10.1097/tp.0000000000001840] [Cited by in Crossref: 39] [Cited by in F6Publishing: 19] [Article Influence: 7.8] [Reference Citation Analysis]
50 Giza P, Ficek R, Dwulit T, Chudek J, Woźniak I, Więcek A, Kolonko A. Number of Regularly Prescribed Drugs and Intrapatient Tacrolimus Trough Levels Variability in Stable Kidney Transplant Recipients. J Clin Med 2020;9:E1926. [PMID: 32575525 DOI: 10.3390/jcm9061926] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
51 Rahamimov R, Tifti-Orbach H, Zingerman B, Green H, Schneider S, Chagnac A, Mor E, Fox BD, Rozen-Zvi B. Reduction of exposure to tacrolimus trough level variability is associated with better graft survival after kidney transplantation. Eur J Clin Pharmacol 2019;75:951-8. [PMID: 30762079 DOI: 10.1007/s00228-019-02643-y] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
52 Yin S, Huang Z, Wang Z, Fan Y, Wang X, Song T, Lin T. Early Monitoring and Subsequent Gain of Tacrolimus Time-In-Therapeutic Range May Improve Clinical Outcomes After Living Kidney Transplantation. Ther Drug Monit 2021;43:728-35. [PMID: 34780391 DOI: 10.1097/FTD.0000000000000881] [Reference Citation Analysis]
53 Prytuła A. Tacrolimus exposure and intra-patient variability in paediatric and young adult kidney transplant recipients: one size does not fit all. Transpl Int 2020;33:1648-9. [PMID: 32964497 DOI: 10.1111/tri.13750] [Reference Citation Analysis]
54 Stefanović NZ, Veličković-Radovanović RM, Danković KS, Mitić BP, Paunović GJ, Cvetković MB, Cvetković TP. Combined Effect of Inter- and Intrapatient Variability in Tacrolimus Exposure on Graft Impairment Within a 3-Year Period Following Kidney Transplantation: A Single-Center Experience. Eur J Drug Metab Pharmacokinet 2020;45:749-60. [PMID: 32886348 DOI: 10.1007/s13318-020-00644-2] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
55 Herblum J, Dacouris N, Huang M, Zaltzman J, Prasad GVR, Nash M, Chen L. Retrospective Analysis of Tacrolimus Intrapatient Variability as a Measure of Medication Adherence. Can J Kidney Health Dis 2021;8:20543581211021742. [PMID: 34188946 DOI: 10.1177/20543581211021742] [Reference Citation Analysis]
56 Gokoel SRM, Zwart TC, Moes DJAR, van der Boog PJM, de Fijter JW. No Apparent Influence of Nonadherence on Tacrolimus Intrapatient Variability in Stable Kidney Transplant Recipients. Ther Drug Monit 2020;42:702-9. [PMID: 32941396 DOI: 10.1097/FTD.0000000000000772] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
57 Vanhove T, Kinashi H, Nguyen TQ, Metalidis C, Poesen K, Naesens M, Lerut E, Goldschmeding R, Kuypers DRJ. Tubulointerstitial expression and urinary excretion of connective tissue growth factor 3 months after renal transplantation predict interstitial fibrosis and tubular atrophy at 5 years in a retrospective cohort analysis. Transpl Int 2017;30:695-705. [PMID: 28390067 DOI: 10.1111/tri.12960] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
58 Sablik KA, Clahsen-van Groningen MC, Hesselink DA, van Gelder T, Betjes MGH. Tacrolimus intra-patient variability is not associated with chronic active antibody mediated rejection. PLoS One 2018;13:e0196552. [PMID: 29746495 DOI: 10.1371/journal.pone.0196552] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 4.8] [Reference Citation Analysis]
59 Del Bello A, Gaible C, Longlune N, Hebral AL, Esposito L, Gandia P, Kamar N. Tacrolimus Intrapatient Variability After Switching From Immediate or Prolonged-Release to Extended-Release Formulation, After an Organ Transplantation. Front Pharmacol 2021;12:602764. [PMID: 34690747 DOI: 10.3389/fphar.2021.602764] [Reference Citation Analysis]
60 Taber DJ, Su Z, Fleming JN, Pilch NA, Morinelli T, Mauldin P, Dubay D. The impact of time-varying clinical surrogates on disparities in African-American kidney transplant recipients - a retrospective longitudinal cohort study. Transpl Int 2019;32:84-94. [PMID: 30176087 DOI: 10.1111/tri.13338] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
61 Thölking G, Filensky B, Jehn U, Schütte-Nütgen K, Koch R, Kurschat C, Pavenstädt H, Suwelack B, Reuter S, Kuypers D. Increased renal function decline in fast metabolizers using extended-release tacrolimus after kidney transplantation. Sci Rep 2021;11:15606. [PMID: 34341448 DOI: 10.1038/s41598-021-95201-5] [Reference Citation Analysis]
62 Stefanović N, Veličković-Radovanović R, Danković K, Pavlović I, Catić-Đorđević A, Bašić J, Despotović M, Jevtović-Stoimenov T, Mitić B, Cvetković T. Effect of the Interrelation between CYP3A5 Genotype, Concentration/Dose Ratio and Intrapatient Variability of Tacrolimus on Kidney Graft Function: Monte Carlo Simulation Approach. Pharmaceutics 2021;13:1970. [PMID: 34834385 DOI: 10.3390/pharmaceutics13111970] [Reference Citation Analysis]
63 Bloom RD, Augustine JJ. Beyond the Biopsy: Monitoring Immune Status in Kidney Recipients. Clin J Am Soc Nephrol 2021:CJN. [PMID: 34362810 DOI: 10.2215/CJN.14840920] [Reference Citation Analysis]
64 Tremblay S, Nigro V, Woodle ES, Alloway RR. Reply to "Fluctuation Does Not Mean Variability: A Pharmacokinetic Point of View". Am J Transplant 2017;17:1693. [PMID: 28248455 DOI: 10.1111/ajt.14248] [Reference Citation Analysis]
65 Lemaitre F, Tron C, Rayar M. Fluctuation Does Not Mean Variability: A Pharmacokinetic Point of View. Am J Transplant 2017;17:1691-2. [DOI: 10.1111/ajt.14237] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
66 Kuypers DRJ. Tacrolimus Formulations and African American Kidney Transplant Recipients: When Do Details Matter? Am J Kidney Dis 2018;71:302-5. [PMID: 29477174 DOI: 10.1053/j.ajkd.2017.10.020] [Cited by in Crossref: 3] [Article Influence: 0.8] [Reference Citation Analysis]
67 Shen CL, Wu BS, Lien TJ, Yang AH, Yang CY. BK Polyomavirus Nephropathy in Kidney Transplantation: Balancing Rejection and Infection. Viruses 2021;13:487. [PMID: 33809472 DOI: 10.3390/v13030487] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
68 Sharma A, Cherukuri A, Mehta RB, Sood P, Hariharan S. High Calcineurin Inhibitor Intrapatient Variability Is Associated With Renal Allograft Inflammation, Chronicity, and Graft Loss. Transplant Direct 2019;5:e424. [PMID: 30882028 DOI: 10.1097/TXD.0000000000000862] [Cited by in Crossref: 4] [Article Influence: 1.3] [Reference Citation Analysis]
69 Prezelin-Reydit M, Dubois V, Caillard S, Parissiadis A, Etienne I, Hau F, Albano L, Pourtein M, Barrou B, Taupin JL, Mariat C, Absi L, Vigneau C, Renac V, Guidicelli G, Visentin J, Merville P, Thaunat O, Couzi L. Prospective Measures of Adherence by Questionnaire, Low Immunosuppression and Graft Outcome in Kidney Transplantation. J Clin Med 2021;10:2032. [PMID: 34068497 DOI: 10.3390/jcm10092032] [Reference Citation Analysis]
70 Davis S, Gralla J, Klem P, Stites E, Wiseman A, Cooper JE. Tacrolimus Intrapatient Variability, Time in Therapeutic Range, and Risk of De Novo Donor–Specific Antibodies. Transplantation 2020;104:881-7. [DOI: 10.1097/tp.0000000000002913] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
71 Okabe M, Morishita T, Ichiki T, Kawaguchi Y, Lee Y, Ohbiki M, Goto M, Osaki M, Araie H, Goto T, Ozawa Y, Miyamura K. The stability of initial tacrolimus concentration following allogeneic hematopoietic stem cell transplantation reduces the risk of acute GVHD. Clin Transplant 2020;34:e14052. [PMID: 33427361 DOI: 10.1111/ctr.14052] [Reference Citation Analysis]
72 Leino AD, King EC, Jiang W, Vinks AA, Klawitter J, Christians U, Woodle ES, Alloway RR, Rohan JM. Assessment of tacrolimus intrapatient variability in stable adherent transplant recipients: Establishing baseline values. Am J Transplant 2019;19:1410-20. [DOI: 10.1111/ajt.15199] [Cited by in Crossref: 37] [Cited by in F6Publishing: 32] [Article Influence: 9.3] [Reference Citation Analysis]
73 Mo H, Kim SY, Min S, Han A, Ahn S, Min SK, Lee H, Ahn C, Kim Y, Ha J. Association of Intrapatient Variability of Tacrolimus Concentration With Early Deterioration of Chronic Histologic Lesions in Kidney Transplantation. Transplant Direct 2019;5:e455. [PMID: 31321291 DOI: 10.1097/TXD.0000000000000899] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
74 McGillicuddy JW, Chandler JL, Sox LR, Taber DJ. Exploratory Analysis of the Impact of an mHealth Medication Adherence Intervention on Tacrolimus Trough Concentration Variability: Post Hoc Results of a Randomized Controlled Trial. Ann Pharmacother 2020;54:1185-93. [PMID: 32506922 DOI: 10.1177/1060028020931806] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]